The social realities of adherence to protease inhibitor regimens: Substance use, health care and psychological states

Journal of Health Psychology

Volumn 10, Issue 4, 2005, Pages 545-558

  Halkitis, Perry N ^a,b   Kutnick, Alexandra H ^a,c   Slater, Simon ^a  

^a NEW YORK UNIVERSITY   (United States)

^b Center for Health Identity Behavior and Prevention Studies (CHIBPS)   (United States)

^c CHIBPS   (United States)

Author keywords

Adherence; Drug use; Gay bisexual; HAART; HIV; MSM

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ALCOHOL; AMPRENAVIR; ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; DIAMORPHINE; INDINAVIR; KETAMINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHAMPHETAMINE; NELFINAVIR; NITRATE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ALCOHOL ABUSE; ARTICLE; COPING BEHAVIOR; CULTURAL FACTOR; DEPRESSION; DRUG ABUSE; DRUG EFFICACY; GUILT; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MEDICAID; MEDICARE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PSYCHOLOGICAL ASPECT; RATING SCALE; SEXUAL BEHAVIOR; SOCIAL ASPECT; SUBSTANCE ABUSE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; NEW YORK CITY; PATIENT COMPLIANCE; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

EID: 22344432685     PISSN: 13591053     EISSN: None     Source Type: Journal    
DOI: 10.1177/1359105305053422     Document Type: Article

References (71)

1. Adam, B. D., Maticka-Tyndale, E., & Cohen, J. J. (2003). Adherence practices among people living with HIV. AIDS Care, 15, 263-274.
2. Bamberger, J. D., Unick, J., Klein, P., Fraser, M., Chesney, M., & Katz, M. H. (2000). Helping the urban poor stay with antiretroviral HIV drug therapy. American Journal of Public Health, 90, 699-701.
3. Bandura, A. (1986). The explanatory and predictive scope of self-efficacy theory. Journal of Social and Clinical Psychology (Special Issue: Self-efficacy theory in contemporary psychology), 4, 359-373.
4. Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Decks, S. G., Perr, S. et al. (2003). High levels of adherence do not prevent accumulation of HIV drug resistant mutations. AIDS, 17, 1925-1932.
5. Batki, S. L., & Ferrando, S. J. (1996). Diagnosis and treatment of substance use disorders in patients with HIV infection. International Review of Psychiatry, 8, 242-252.
6. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 562-571.
7. Besch, L. C. (1995). Compliance in clinical trials. AIDS, 9, 1-10.
8. Bing, E. G., Burnam, M. A., Longshore, D., Fleishman, J. A., Sherbourne, C. D., London, A. S. et al. (2001). Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry, 58, 721-728.
9. Bondi, M. W., Drake, A. I., & Grand, I. (1998). Verbal learning and memory in alcohol abusers and poly-substance abusers with concurrent alcohol abuse. Journal of the International Neuropsychological Society, 4, 319-328.
10. Bybee, J. A., & Ziegler, E. (1991). Self-image and guilt: A further test of the cognitive-developmental formulation. Journal of Personality, 59, 733-745.
11. Carrieri, P., Cailleton, V., Le Moing, B., Spire, B., Dellamonica, P., Boubet, E. et al. (2001). The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndrome, 28, 232-239.
12. Center for Disease Control. (2003). Increases in HIV diagnoses-29 states, 1999-2002. Morbidity and Mortality Weekly Report, 52(47), 1145-1148.
13. Cook, J. A., Cohen, M. H., Grey, D., Kirstein, L., Burke, J., Anastos, K. et al. (2002). Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. American Journal of Public Health, 92, 82-87.
14. Crystal, S., Sambamoorthi, U., Moynihan, P. J., & McSpiritt, E. (2001). Initiation and continuation of newer antiretroviral treatments among Medicaid recipients with AIDS. Journal of General Internal Medicine, 16, 850-859.
15. Demas, P., Schoenbaum, E. E., Hirky, A. E., Wills, T. A., Doll, L. S., Hartel, D. M. et al. (1998). The relationship of HIV treatment acceptance and adherence to psychosocial factors among injecting drug users. AIDS and Behavior, 2, 283-292.
16. Demmer, C. (2003). Attitudes toward HIV protease inhibitors and medication adherence in an inner city HIV population. AIDS Patient Care and STDS, 17, 575-580.
17. Eldred, L. J., Wu, A. W., Chaisson, R. E., & Moore, R. D. (1998). Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. Journal of Acquired Immune Deficiency Syndromes and Human Relrovirology, 18, 117-125.
18. Folkman, S., Chesney, J., Pollack, L., & Coates, T. (1993). Stress, control, coping, and depressive mood in human immunodeficiency virus-positive and - negative gay men in San Francisco. Journal of Nervous and Mental Disease, 181, 409-416.
19. Freeman, R. C., Rodriguez, G. M., & French, J. F. (1996). Compliance with AZT treatment regimen of HIV-seropositive injection drug users: A neglected issue. AIDS Education and Prevention, 8, 58-71.
20. Gifford, A. L., Bormann, J. E., Shively, M. J., Wright, B. C., Richman, D., & Bozzette, S. A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndrome, 23, 386-395.
21. Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1763-1769.
22. Halkitis, P. N., & Kirton, C. (1999). Self-strategies as means of enhancing adherence to HIV antiretroviral therapies: A Rogerian approach. Journal of the New York State Nurses Association, 14, 1-5.
23. Halkitis, P. N., Parsons, J. T., Wolitski, R., & Remien, R. H. (2003). Characteristics of HIV antiretroviral treatments, access and adherence in an ethnically diverse sample of men who have sex with men. AIDS Care, 15, 89-102.
24. Halkitis, P. N., Zade, D., Shrem, M., & Wilton, L. (2005). The physical, emotional, and interpersonal impact of HAART on the lives of seropositive individuals: Physical, psychological, and social realities. Journal of Health Psychology, 10, 345-358.
25. Haubrich, R., Little, S., Dube, M., Forthal, D., Beall, G., Kemper, C. et al. (1998). Self reported treatment adherence and drug/alcohol use are associated with virologic outcomes in CCTG 570: A clinical strategy trial of HIV RNA antiRetroviral (ARV) monitoring. Poster presented at the 12th World AIDS Conference, Geneva, Switzerland, June.
26. Hill, Z., Kendall, C., & Fernandez, M. (2003). Patterns of adherence to antiretrovirals: Why adherence has no simple measure. AIDS Patient Care and STDS, 17, 519-525.
27. Hirschhorn, L., Quinones, J., Goldin, S., & Metras, L. (1998). Highly Active Anti-Retroviral Therapy (HAART) in the 'real world': Experiences in an inner-city community health center (CHC). Poster presented at the 12th World AIDS Conference, Geneva, Switzerland, June.
28. Ho, D. D., Neuman, A. U., Perelson, A. S., Chen, W., Leonard, J. M., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 373, 123-126.
29. Holahan, C. J., & Moos, R. H. (1987). Personal and contextual determinants of coping strategies. Journal of Personality and Social Psychology, 52, 946-955.
30. Hugen, P. W., Langebeek, N., Burger, D. M., van Leusen, R., Schuurman, R., & Koopman, P. P. et al. (2002). Assessment of adherence to HIV protease inhibitors: Comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. Journal of Acquired Immune Deficiency Syndrome, 30, 324-334.
31. Ickovics, J. (1997). Measures of adherence. Paper presented at Adherence to new HIV therapies: A research conference, Washington, DC, November.
32. Ickovics, J. R., & Meisler, A. W. (1996). Adherence in AIDS clinical trials: A framework for clinical research and clinical care. American Journal of Medicine, 92, 492-502.
33. Kalichman, S. C., Catz, S., & Ramachandran, B. (1999). Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. Journal of the National Medical Association, 91, 439-446.
34. Kalichman, S. C., DiFonzo, K., Austin, J., Luke, W., & Rompa, D. (2002). Prospective study of emotional reactions to changes in HIV viral load. AIDS Patient Care and STDs, 16, 113-120.
35. Kappes, J. C., Saag, M. S., Shaw, G. M., Hahn, B. H., Chopra, P., Chen, S. et al. (1995). Assessment of antiretroviral therapy by plasma viral load testing: Standard and ICD HIV-1 antigen and viral RNA (QC-PCR) assays compared. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10, 139-149.
36. Kastrissios, H., Suarez, J. R., Katzenstein, D., Girard, P., Sheiner, L. B., & Blaschke, T. F. (1998). Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS, 12, 2295-2303.
37. Kruse, W., Rampmaier, J., Ullrich, G., & Weber, E. (1994). Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. international Journal of Clinical Pharmacology Therapy, 32, 453-457.
38. Leslie, M. B., Stein, J. A., & Rotheram-Borus, M. J. (2002). The impact of coping strategies, personal relationships, and emotional distress on health-related outcomes of parents living with HIV or AIDS. Journal of Social and Personal Relationships (Special Issue: Personal and social relationships of individuals living with HIV and/or AIDS), 19, 45-66.
39. Low-Beer, S., Yip, B., O'Shaughnessy, M. V., Hogg, R. S., & Montaner, J. S. G. (2000). Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndrome, 23, 360-361.
40. Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 16, 767-774.
41. Mannheimer, S., Friedland, G., Matts, J. Child, C., & Chesney, M. (2002).The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34, 1115-1121.
42. Matsuyama, J. R., Mason, B. J., & Jue, S. G. (1995). Pharmacists' interventions using an electronic medication-event monitoring device's adherence data versus pill counts. Annals of Pharmacotherapy, 27, 851-855.
43. McNabb, J., Ross, J. W., Abriola, K., Turley, C., Nightingale, C. H., & Nicolau, D. P. (2001). Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases, 33, 700-705.
44. Misener, T. R., & Sowell, R. L. (1998). HIV infected women's decisions to take antiretrovirals. Western Journal of Nursing Research, 20, 431-447.
45. Montaner, J. S., Harris, M., Mo, T., & Harrigan, P. R. (1998). Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS, 12, 1398-1399.
46. Murphy, D. A., Greenwell, L., & Hoffman, D. (2002). Factors associated with antiretroviral adherence among HIV-infected women with children. Women Health, 36, 97-111.
47. Murphy, D. A., Roberts, K. J., Martin, D. J., Marelich, W., & Hoffman, D. (2000). Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care and STDs, 14, 47-58.
48. Patterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squire, C. et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
49. Power, R., Koopman, C., Volk, J., Israelski, D. M., Stone, L., Chesney, M. A. et al. (2003). Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons. AIDS Patient Care and STDs, 17, 245-252.
50. Roberts, K. J. (2000). Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care and STDs, 14, 155-168.
51. Rosenstock, I. M. (1974). Historical origins of the health belief model. Health Education Monographs, 2, 328-335.
52. Rosseli, M., & Ardila, A. (1996). Cognitive effects of cocaine and polydrug abuse. Journal of Clinical and Experimental Neuropsychology, 18, 122-135.
53. Routy, J. P., Brenner, B., Salomon, H., Quan, Y., Campos, A. F., Rouleau, D. et al. (2000). Transmission of dual and triple-class drug resistant viral variants in prmary/early HIV-1 infection (PHI) in Montreal. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February.
54. Russell, C. K., Bunting, S. M., Graney, M., Hartig, M. T., Kisner, P., & Brown, B. (2003). Factors that influence the medication decision making of person with HIV/AIDS: A taxonomic exploration. Journal of the Association of Nurses in AIDS Care, 14, 46-60.
55. Siegel, K., Karus, D., & Schrimshaw, E. W. (2000). Racial differences in attitudes toward protease inhibitors among older HIV-infected men. AIDS Care, 12, 423-434.
56. Simoni, J. M., Frick, P. A., Lockhart, D., & Liebovitz, D. (2002). Mediators of social support and antiretroviral adherence among an indigent population in New York City. AIDS Patient Care and STDs, 16, 431-439.
57. Sobell, L. C., & Sobell, M. B. (1992). Timeline follow-back: A technique for assessing self-reported alcohol consumption. In R. Litton & J. P. Allen (Eds.), Measuring alcohol consumption: Psychosocial and biochemical methods (pp. 41-69). Totowa, NJ: Humana Press.
58. Spire, B., Segolene, D., Souville, M., Leport, C., Raffi, F., & Moatti, J. (2002). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Social Sciences and Medicine, 54, 1481-1496.
59. Stall, R., Hoff, C., Coates, T. J., Paul, J., Phillips, K. A., Ekstrand, M. et al. (1996). Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: Implications for secondary prevention efforts. Journal of Acquired Immune Deficiency Syndrome Human Retrovirology, 11, 151-160.
60. Stone, V. E., Adelson-Mitty, J., Duefield, C. A., Steger, K. A., Stein, M. D., & Mayer, K. H. (1998). Adherence to protease inhibitor (PI) therapy in clinical practice: Usefulness of demographics, attitudes and knowledge as predictors. Poster presented at the 12th World AIDS Conference, Geneva, Switzerland, June.
61. Swindell, S., Mohr, J., Justis, J. C., Berman, S., Squier, C., Wagener, M. M. et al. (1999). Quality of life in patients with human immunodeficiency virus infection: Impact of social support, coping style and hopelessness. International Journal of STDs and AIDS, 10, 338-389.
62. Treisman, G. J., Angelina, A. F., & Hutton, H. E. (2001). Psychiatric issues in the management of patients with HIV infection. Journal of the American Medical Academy, 286, 2857-2864.
63. Turner, C. F., Ku, L., Rogers, S. M., Lindberg, L. D., Pleck, J. H., & Sonerstein, F. L. (1998). Adolescent sexual behavior, drug use, and violence: Increased reporting with computer survey technology. Science, 280, 867-873.
64. Turner, J. G., Nokes, K. M., Corless, I. B., Holzerner, W. L., Inouye, J., Brown, M. A. et al. (1998). History of drug use and adherence in HIV+ persons. Paper presented at the 12th World AIDS Conference, Geneva, Switzerland, June.
65. Van Wijngarden, E., de Saar, V., de Graeve, V., Vandamme, A. M., van Vaerenbergh, K., Bobbaers, H. et al. (2002). Nonadherence to highly active antiretroviral therapy: Clinically relevant patient categorization based on electronic event monitoring. AIDS Research and Human Retroviruses, 18, 327-330.
66. Wagner, G. J., & Rabkin, J. G. (2000). Measuring medication adherence: Are missed doses reported more accurately than perfect adherence? AIDS Care, 12, 405-408.
67. Wainberg, M. A., & Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. Journal of the American Medical Association, 279, 1977-1980.
68. Waterhouse, D. M., Calzone, K. A., Mele, C., & Brenner, D. E. (1993). Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. Journal of Clinical Oncology, 11, 1189-1197.
69. Watters, J. K., & Biernacki, P. (1989). Targeted sampling: Options and considerations for the study of hidden populations. Social Problems, 36, 416-430.
70. Williams, A., Wolf, H., Yu, C., & Singh, M. (1998). Adherence to antiretroviral therapy among HIV positive women. Poster presented at the 12th International AIDS Conference, Geneva, Switzerland, June.
71. Witteveen, E., & van Ameijden, E. J. C. (2002). Drug users and HIV-combination therapy (HAART): Factors which impede or facilitate adherence. Substance Use and Misuse, 37, 1905-1925.